Abstract
AbstractChanges to the gut microbiota are reported in type 2 diabetes. The activity of the microbiota is integral in maintaining intestinal barrier function, disruption to which is proposed as a risk factor for the low‐grade inflammation associated with insulin resistance. Can we target the microbiota through diet, and more specifically with prebiotics to improve barrier function and ultimately glycaemic control? This narrative review will discuss the evidence for barrier dysfunction in human type 2 diabetes and outline the recent evidence from clinical trials investigating the efficacy of prebiotics in glucose management. Copyright © 2020 John Wiley & Sons.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
